Stable IgG-antibody levels in patients with mild SARS-CoV-2 infection

  1. Thomas Åkerlund
  2. Katherina Zakikhany
  3. Charlotta Löfström
  4. Evelina Lindmark
  5. Henrik Källberg
  6. Ulla Elofsson
  7. Karin Cederbrant
  8. Erik Nygren
  9. Anders Kallin
  10. Nina Lagerqvist
  11. Peter Nilsson
  12. Sophia Hober
  13. Anna Ridderstad Wollberg
  14. Åsa Szekely Björndal

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

More knowledge regarding persistence of antibody response to SARS-CoV-2 infections in the general population with mild symptoms is needed. We measured and compared levels of SARS-CoV-2 spike- and nucleocapsid-specific IgG-antibodies in serum samples from 145 laboratory-confirmed COVID-19 cases and 324 non-cases. The IgG-antibody levels against the spike protein in cases were stable over the time-period studied (14 to 256 days), while antibody levels against the nucleocapsid protein decreased over time.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2021.06.16.21258960: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Written consent was obtained from all study-participants.
    Field Sample Permit: Serum sampling: Venous blood (5-40 mL) was collected into Serum Sampling Tubes (SST BD Vacutainer) on county level and transported at ambient temperature to regional laboratories for centrifugation and isolation of serum.
    IRB: Ethical approval and financing: Ethical approval for this study was obtained from the Swedish Ethical Review Board: Dnr 2020-03584.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    BlindingTesting was performed blinded, i.e. without disclosing any case information of the samples.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The purpose of the questionnaire was to pre-screen for candidates likely to donate either antibody-positive or negative serum samples, as well as to allow for weighing of samples regarding gender, age, county of residence (county 1-3) and symptoms of respiratory tract infection (RTI) other than COVID-19.
    antibody-positive
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2021.06.16.21258960v1 on medRxiv